Genta Inc. is Today's Focus Stock on MicroStockProfit.com

This version of Wbna41035819 - Breaking News | NBC News Clone was adapted by NBC News Clone to help readers digest key facts more efficiently.

DALLAS, Jan. 12, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Genta Inc. (OTCBB:GNTA). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

DALLAS, Jan. 12, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Genta Inc. (OTCBB:GNTA). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at:

Genta (OTCBB:GNTA) is a biopharmaceutical company engaged in pharmaceutical research and development. It is dedicated to the identification, development and commercialization of novel drugs for the treatment of cancer and related diseases. The Company's research portfolio consists of two major programs: "DNA/RNA Medicines" (which includes its lead oncology drug, Genasense®); and "Small Molecules" (which includes its marketed product, Ganite®, and tesetaxel and oral gallium-containing compounds). 

For only $19 a month, you can sign up for our real-time stock alert service. Click here to join now:

In the report, the analyst notes:

"GNTA recently provided an update of its research and development activities in conjunction with its presentation at this year's Biotech Showcase in San Francisco.

"GNTA said it has initiated and completed more randomized phase III trials with Genasense than any other company. It also said it has completed accrual in two randomized phase III trials of Genasense in patients with advanced melanoma."

To read the entire report visit:

See what investors are saying about GNTA at

Get breaking news on GNTA at

MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit:

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.

CONTACT: Brian Johnson info@microstockprofit.com 1-888-307-2850
×
AdBlock Detected!
Please disable it to support our content.

Related Articles

Donald Trump Presidency Updates - Politics and Government | NBC News Clone | Inflation Rates 2025 Analysis - Business and Economy | NBC News Clone | Latest Vaccine Developments - Health and Medicine | NBC News Clone | Ukraine Russia Conflict Updates - World News | NBC News Clone | Openai Chatgpt News - Technology and Innovation | NBC News Clone | 2024 Paris Games Highlights - Sports and Recreation | NBC News Clone | Extreme Weather Events - Weather and Climate | NBC News Clone | Hollywood Updates - Entertainment and Celebrity | NBC News Clone | Government Transparency - Investigations and Analysis | NBC News Clone | Community Stories - Local News and Communities | NBC News Clone